

05-24-02

RECEIVED 1614

MAY 29 2002

TECH CENTER 1008-000

Please type a plus sign (+) inside this box → ☒Approved for use through 10/31/2002. OMB 085-1008-000
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/069,180	
	Filing Date	2/15/2002	
	First Named Inventor	OHKAWA, S.	
	Group Art Unit	1614	
	Examiner Name	tba	
Total Number of Pages in This Submission	6	Attorney Docket Number	2628 USOP

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Return Postcard.
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	Certificate of Express Mailing Form PTO 1449
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	Cited References (6)
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account 500799.
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Mark Chao, Ph.D., JD, Reg. No. 37,293
Signature	
Date	5/23/02

CERTIFICATE OF MAILING		
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: <u>5/23/02</u>		
Typed or printed name	Gail L. Winokur	
Signature		Date <u>5/23/02</u>

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Express Mail # EV 082675174 US

#5
#23
#40
RECEIVED
MAY 29 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/069,180

Filed: 2/15/2002

1st Inventor: OHKAWA, S.

For: Tricyclic Dihydrobenzofuran derivatives,
process for the preparation thereof and
agents

Atty. Dkt. No. 2628 USOP



Art. Unit: 1614

Examiner: tba

Allowed:

Batch:

Paper No.:

Information Disclosure Statement

Commissioner for Patents
Washington, D.C. 20231
Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, applicants request consideration of the references listed on the attached form PTO-1449. A legible copy of each listed reference has been previously submitted to the Patent Office in prior patent application Serial No. 09/254,446.

This information disclosure statement is being submitted before the mailing date of the first Office Action on the merits, thus, no certification or fee is required.

For each non-English language reference listed on the attached Form PTO-1449, reference is made to the concise explanation attached thereto in English.

Applicants respectfully request that the listed documents be considered by the Examiner and formally be made of record in the present application and that an initialed copy of the attached Form PTO-1449 be returned in accordance with MPEP §9609.

Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, the Examiner is respectfully invited to call applicants' attorney.

Respectfully submitted,

Dated: May 23, 2002

(847)383-3372

(847)383-3391

Mark Chao, Ph.D., Reg. No. 37,293

Elaine M. Ramesh, Ph.D., Reg. No. 43032

Attorney for Applicants

Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
Suite 500, 475 Half Day Road
Lincolnshire, IL 60069 USA



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/069,180
Filed: 2/15/2002
1st Inventor: OHKAWA, S.
For: Tricyclic Dihydrobenzofuran Derivatives, Process for
the Preparation Thereof and Agents
Atty. Dkt. No. 2628 USOP

Art Unit: 1614
Examiner: tba
Allowed:
Batch:
Paper No.:
TECH CENTER 1600/2900
MAY 29 2002

RECEIVED

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

USPS EXPRESS MAIL LABEL. No. EV 082675174 US

DATE IN: May 23, 2002

Itemized Papers/Items:


1. This certificate and a Return Receipt Postcard (2 pgs.)
2. Transmittal Form (1 pg. X 2)
3. Information Disclosure Statement, PTO Form 1449 (2 pages), and copies of cited references (7)

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

Commissioner for Patents
Washington, D.C. 20231.

on this date, 5/23/02

Dated: 5/23/02


Gail L. Winokur

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
Suite 500, 475 Half Day Road
Lincolnshire, IL 60069 USA